Sarepta Therapeutics Inc. is planning to appeal the expected knock-back of its EU marketing authorization application (MAA) for the controversial drug eteplirsen.
A negative opinion on the MAA from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is...








